Business

Arrhythmia’s quarterly loss widens

A plastinated human heart was displayed at a European cardiology conference.
Reuters/File 2013
A plastinated human heart was displayed at a European cardiology conference.

Arrhythmia Research Technology Inc.’s quarterly net loss widened to $2.89 million, or $1.06 per share, from $1.04 million, or 37 cents, in the same quarter last year. But the Fitchburg company’s total consolidated revenue from continuing operations grew 1.8 percent, to $4.88 million, from a year before. The company and its Micron Products subsidiary supply products for the medical and defense industries, including software to detect certain heart arrhythmias.